



**MEDIA CONTACT:**

Lisa Kornblatt  
SS|PR  
847-415-9330  
[lkornblatt@sspr.com](mailto:lkornblatt@sspr.com)

**InVivo Therapeutics' CEO Frank Reynolds Scheduled to Appear on KSTP-TV (ABC) and KMSP-TV (FOX) in Minneapolis To Discuss Paralyzing Injuries To Local High School Hockey Players**

*CEO to Discuss the Company's Latest Advances in Spinal Cord Injury Treatment on January 15<sup>th</sup> and January 16<sup>th</sup>*

**CAMBRIDGE, Mass. (January 12, 2011) – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV)**, a developer of groundbreaking technologies for the [treatment of spinal cord injuries](#) (SCI), today announced that CEO Frank Reynolds is scheduled to appear on Minneapolis' ABC affiliate, KSTP-TV, on Sunday, January 15<sup>th</sup> during the 8:00 AM (CST) newscast and the FOX affiliate, KMSP-TV, on Monday, January 16<sup>th</sup> during their 8:00 AM (CST) newscast.

InVivo Therapeutics has pioneered a new treatment platform that uses a biocompatible polymer-based scaffold to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving recovery and prognosis after a traumatic spinal cord injury. Reynolds will discuss the scaffold and how it is expected to work in humans, as well as results from InVivo's largest non-human primate study.

"The recent spinal cord injuries of two local high school hockey players magnify the need for SCI treatments. Our therapeutic approach confirms a clear paradigm shift in the care of such injuries and we expect that our technology will change the standard treatment for SCI," said Reynolds. "We're currently under review at FDA and we look forward to receiving approval to begin human studies. Having worked in conjunction with the Boston Bruins Foundation and with hockey players injured in New England, we understand the needs that these players and their families will have, and we look forward to helping in any way that we can."

KMSP-TV is the local FOX affiliate and KSTP-TV is the local ABC affiliate in Minneapolis.

**About InVivo Therapeutics**

InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The company was founded in 2005 based on proprietary technology co-invented by Robert S. Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious 2011 David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, Mass. For more details, visit [www.invivotherapeutics.com](http://www.invivotherapeutics.com).

## Safe Harbor Statement

*Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our Form 10-K and Form 10-Qs and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.*

# # #